Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease

被引：40

作者：

Rodriguez-Lago, Iago ^{[1
,2
]}

Hoyo, Javier Del ^{[3
,4
]}

Perez-Girbes, Alexandre ^{[5
]}

Garrido-Marin, Alejandro ^{[3
]}

Casanova, Maria Jose ^{[4
,6
,7
]}

Chaparro, Maria ^{[4
,6
,7
]}

Fernandez-Clotet, Agnes ^{[4
,8
]}

Castro-Poceiro, Jesus ^{[8
]}

Garcia, Maria Jose ^{[9
]}

Sanchez, Sara ^{[10
]}

Ferreiro-Iglesias, Rocio ^{[11
]}

Baston, Iria ^{[11
]}

Piqueras, Marta ^{[12
]}

Careda, Lola Esteba i Bech de Careda ^{[13
]}

Mena, Raquel ^{[12
]}

Suarez, Cristina ^{[14
]}

Cordon, Joaquin Poza ^{[14
]}

Lopez-Garcia, Alicia ^{[15
,16
]}

Marquez, Lucia ^{[15
,16
]}

Arroyo, Maite ^{[4
,17
]}

Alfambra, Erika ^{[4
,17
]}

Sierra, Monica ^{[18
]}

Cano, Noelia ^{[18
]}

Delgado-Guillena, Pedro ^{[19
]}

Morales-Alvarado, Victor ^{[19
]}

Aparicio, Juan Carlos ^{[20
]}

Guerra, Ivan ^{[21
,22
]}

Aullo, Carolina ^{[23
]}

Merino, Olga ^{[24
]}

Arranz, Laura ^{[25
]}

Hidalgo, Maria Araceli ^{[26
]}

Llao, Jordina ^{[27
]}

Plaza, Rocio ^{[28
]}

Molina, Gema ^{[29
]}

Torres, Paola ^{[30
]}

Perez-Galindo, Pablo ^{[31
]}

Romero, Maria Giselle ^{[32
]}

Herrera-deGuise, Claudia ^{[33
]}

Armesto, Edisa ^{[34
]}

Mesonero, Francisco ^{[35
]}

Frago-Larramona, Santiago ^{[36
]}

Benitez, Jose Manuel ^{[37
,38
]}

Calvo, Marta ^{[39
]}

Martin, Maria del Carmen Lopez ^{[40
]}

Elorza, Ainara ^{[1
,2
]}

Larena, Alejandro ^{[41
]}

Pena, Elena ^{[42
]}

Rodriguez-Grau, Maria del Carmen ^{[43
]}

Miguel-Criado, Jaime de ^{[44
]}

Botella, Belen ^{[45
]}

机构：

[1] Hosp Galdakao, Gastroenterol, Galdakao, Spain

[2] Biocruces Bizkaia Hlth Res Inst, Baracaldo, Spain

[3] Hosp Univ & Politecn La Fe, Gastroenterol, Valencia, Spain

[4] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

[5] Hosp Univ & Politecn La Fe Valencia, Radiol, Valencia, Spain

[6] Hosp Univ La Princesa, Gastroenterol, Madrid, Spain

[7] Univ Autonoma Madrid UAM, Inst Invest Sanit Princesa IIS IP, Madrid, Spain

[8] Hosp Clin Barcelona, Gastroenterol, Barcelona, Spain

[9] Hosp Univ Marques Valdecilla, Gastroenterol, Santander, Spain

[10] Hosp Univ Marques Valdecilla, Radiol, Santander, Spain

[11] Hosp Clin Univ Santiago De Compostela, Gastroenterol, Santiago De Compostela, Spain

[12] Consorci Sanit Terrassa, Gastroenterol, Terrassa, Spain

[13] Consorci Sanit Terrassa, Radiol, Terrassa, Spain

[14] Hosp Univ La Paz, Gastroenterol, Madrid, Spain

[15] Hosp del Mar, Gastroenterol, Barcelona, Spain

[16] Hosp del Mar, Med Res Inst IMIM, Barcelona, Spain

[17] Hosp Clin Univ Lozano Blesa, IIS Aragon, Gastroenterol, Zaragoza, Spain

[18] Complejo Asistencial Univ Leon, Gastroenterol, Leon, Spain

[19] Hosp Gen Granollers, Gastroenterol, Granollers, Spain

[20] Hosp Gen Granollers, Radiol, Granollers, Spain

[21] Hosp Univ Fuenlabrada, Gastroenterol, Fuenlabrada, Spain

[22] Inst Invest La Paz IdiPaz, Madrid, Spain

[23] Hosp Univ Fuenlabrada, Radiol, Fuenlabrada, Spain

[24] Hosp Univ Cruces, Gastroenterol, Baracaldo, Spain

[25] Hosp Ntra Sra Candelaria, Gastroenterol, Santa Cruz De Tenerife, Spain

[26] Hosp Ntra Sra Candelaria, Radiol, Santa Cruz De Tenerife, Spain

[27] Xarxa Assistencial Univ Manresa, Althaia, Gastroenterol, Manresa, Spain

[28] Hosp Univ Infanta Leonor, Gastroenterol, Madrid, Spain

[29] Complejo Hosp Univ Ferrol, Gastroenterol, Ferrol, Spain

[30] Hosp Badalona Germans Trias & Pujol, Gastroenterol, Badalona, Spain

[31] Hosp Montecelo, Gastroenterol, Pontevedra, Spain

[32] Hosp Montecelo, Radiol, Pontevedra, Spain

[33] Hosp Univ Vall dHebron, Gastroenterol, Barcelona, Spain

[34] Hosp San Agustin, Gastroenterol, Aviles, Spain

[35] Hosp Univ Ramon y Cajal, Gastroenterol, Madrid, Spain

[36] Hosp Santa Barbara, Gastroenterol, Soria, Spain

[37] Hosp Univ Reina Sofia, Gastroenterol, Cordoba, Spain

[38] IMIBIC, Cordoba, Spain

[39] Hosp Puerta Hierro, Gastroenterol, Madrid, Spain

[40] Hosp Univ Infanta Elena, Gastroenterol, Valdemoro, Spain

[41] Osatek, Galdakao, Spain

[42] Hosp Royo Villanova, Gastroenterol, Zaragoza, Spain

[43] Hosp Univ Henares, Gastroenterol, Coslada, Spain

[44] Hosp Univ Henares, Radiol, Coslada, Spain

[45] Hosp Univ Infanta Cristina, Gastroenterol, Parla, Spain

[46] Hosp Univ Rey Juan Carlos, Gastroenterol, Mostoles, Spain

[47] Hosp Univ Sant Joan Reus, Gastroenterol, Reus, Spain

[48] Hosp Galdakao, Res Unit, Red Invest Serv Salud Enfermedades Cron REDISSEC, Galdakao, Spain

来源：

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL | 2020年 / 8卷 / 09期

关键词：

Anti-TNF; biologic drug; Crohn's disease; stricture; surgery; BOWEL DAMAGE; EFFICACY; FIBROSIS; IMMUNOMODULATORS; INFLAMMATION; ANTAGONISTS; MANAGEMENT; MECHANISMS; INFLIXIMAB; CONSENSUS;

D O I：

10.1177/2050640620947579

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background There is limited evidence on the effectiveness of biological therapy in stricturing complications in patients with Crohn's disease. Aim The study aims to determine the effectiveness of anti-tumor necrosis factor (TNF) agents in Crohn's disease complicated with symptomatic strictures. Methods In this multicentric and retrospective study, we included adult patients with symptomatic stricturing Crohn's disease receiving their first anti-TNF therapy, with no previous history of biological, endoscopic or surgical therapy. The effectiveness of the anti-TNF agent was defined as a composite outcome combining steroid-free drug persistence with no use of new biologics or immunomodulators, hospital admission, surgery or endoscopic therapy during follow-up. Results Overall, 262 patients with Crohn's disease were included (53% male; median disease duration, 35 months, 15% active smokers), who received either infliximab (N = 141, 54%) or adalimumab (N = 121, 46%). The treatment was effective in 87% and 73% of patients after 6 and 12 months, respectively, and continued to be effective in 26% after a median follow-up of 40 months (IQR, 19-85). Nonetheless, 15% and 21% of individuals required surgery after 1 and 2 years, respectively, with an overall surgery rate of 32%. Postoperative complications were identified in 15% of patients, with surgical site infection as the most common. Starting anti-TNF therapy in the first 18 months after the diagnosis of Crohn's disease or the identification of stricturing complications was associated with a higher effectiveness (HR 1.62, 95% CI 1.18-2.22; and HR 1.55, 95% CI 1.1-2.23; respectively). Younger age, lower albumin levels, strictures located in the descending colon, concomitant aminosalicylates use or presence of lymphadenopathy were associated with lower effectiveness. Conclusions Anti-TNF agents are effective in approximately a quarter of patients with Crohn's disease and symptomatic intestinal strictures, and 68% of patients are free of surgery after a median of 40 months of follow-up. Early treatment and some potential predictors of response were associated with treatment success in this setting.

引用

页码：1056 / 1066

页数：11

共 28 条

[1] Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience [J].

Allocca, Mariangela ;

Bonifacio, Cristiana ;

Fiorino, Gionata ;

Spinelli, Antonino ;

Furfaro, Federica ;

Balzarini, Luca ;

Bonovas, Stefanos ;

Danese, Silvio .

DIGESTIVE AND LIVER DISEASE, 2017, 49 (08) :872-877

[2] A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohn's Disease [J].

Bettenworth, Dominik ;

Gustavsson, Anders ;

Atreja, Ashish ;

Lopez, Rocio ;

Tysk, Curt ;

van Assche, Gert ;

Rieder, Florian .

INFLAMMATORY BOWEL DISEASES, 2017, 23 (01) :133-142

[3] Therapeutic Armamentarium for Stricturing Crohn's Disease: Medical Versus Endoscopic Versus Surgical Approaches [J].

Bharadwaj, Shishira ;

Fleshner, Phillip ;

Shen, Bo .

INFLAMMATORY BOWEL DISEASES, 2015, 21 (09) :2194-2213

[4] Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study [J].

Bouhnik, Yoram ;

Carbonnel, Franck ;

Laharie, David ;

Stefanescu, Carmen ;

Hebuterne, Xavier ;

Abitbol, Vered ;

Nachury, Maria ;

Brixi, Hedia ;

Bourreille, Arnaud ;

Picon, Laurence ;

Bourrier, Anne ;

Allez, Matthieu ;

Peyrin-Biroulet, Laurent ;

Moreau, Jacques ;

Savoye, Guillaume ;

Fumery, Mathurin ;

Nancey, Stephane ;

Roblin, Xavier ;

Altwegg, Romain ;

Bouguen, Guillaume ;

Bommelaer, Gilles ;

Danese, Silvio ;

Louis, Edouard ;

Zappa, Magaly ;

Mary, Jean-Yves .

GUT, 2018, 67 (01) :53-+

[5] Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study [J].

Burisch, Johan ;

Kiudelis, Gediminas ;

Kupcinskas, Limas ;

Kievit, Hendrika Adriana Linda ;

Andersen, Karina Winther ;

Andersen, Vibeke ;

Salupere, Riina ;

Pedersen, Natalia ;

Kjeldsen, Jens ;

D'Inca, Renata ;

Valpiani, Daniela ;

Schwartz, Doron ;

Odes, Selwyn ;

Olsen, Jongero ;

Nielsen, Kari Rubek ;

Vegh, Zsuzsanna ;

Lakatos, Peter Laszlo ;

Toca, Alina ;

Turcan, Svetlana ;

Katsanos, Konstantinos H. ;

Christodoulou, Dimitrios K. ;

Fumery, Mathurin ;

Gower-Rousseau, Corinne ;

Zammit, Stefania Chetcuti ;

Ellul, Pierre ;

Eriksson, Carl ;

Halfvarson, Jonas ;

Magro, Fernando Jose ;

Duricova, Dana ;

Bortlik, Martin ;

Fernandez, Alberto ;

Hernandez, Vicent ;

Myers, Sally ;

Sebastian, Shaji ;

Oksanen, Pia ;

Collin, Pekka ;

Goldis, Adrian ;

Misra, Ravi ;

Arebi, Naila ;

Kaimakliotis, Ioannis P. ;

Nikuina, Inna ;

Belousova, Elena ;

Brinar, Marko ;

Cukovic-Cavka, Silvija ;

Langholz, Ebbe ;

Munkholm, Pia ;

Niewiadomski, Ola ;

Bell, Sally ;

Turk, Niksa ;

Cukovic-Cavka, Silvija .

GUT, 2019, 68 (03) :423-433

[6] Medical Therapies for Stricturing Crohn's Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure [J].

Campos, Cecile ;

Perrey, Antoine ;

Lambert, Celine ;

Pereira, Bruno ;

Goutte, Marion ;

Dubois, Anne ;

Goutorbe, Felix ;

Dapoigny, Michel ;

Bommelaer, Gilles ;

Hordonneau, Constance ;

Buisson, Anthony .

DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (06) :1628-1636

[7] Impact of therapies on bowel damage in Crohn's disease [J].

Fiorino, Gionata ;

Bonifacio, Cristiana ;

Allocca, Mariangela ;

Danese, Silvio .

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (04) :410-417

[8] Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome [J].

Fiorino, Gionata ;

Morin, Mathilde ;

Bonovas, Stefanos ;

Bonifacio, Cristiana ;

Spinelli, Antonino ;

Germain, Adeline ;

Laurent, Valerie ;

Zallot, Camille ;

Peyrin-Biroulet, Laurent ;

Danese, Silvio .

JOURNAL OF CROHNS & COLITIS, 2017, 11 (03) :274-280

[9] Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study [J].

Frei, Roy ;

Fournier, Nicolas ;

Zeitz, Jonas ;

Scharl, Michael ;

Morell, Bernhard ;

Greuter, Thomas ;

Schreiner, Philipp ;

Misselwitz, Benjamin ;

Safroneeva, Ekaterina ;

Schoepfer, Alain M. ;

Vavricka, Stephan R. ;

Rogler, Gerhard ;

Biedermann, Luc .

JOURNAL OF CROHNS & COLITIS, 2019, 13 (10) :1292-1301

[10] Therapy for Fibrotic Diseases: Nearing the Starting Line [J].

Friedman, Scott L. ;

Sheppard, Dean ;

Duffield, Jeremy S. ;

Violette, Shelia .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (167)

← 1 2 3 →